MedDataX Logo

Study Evaluating Etanercept in Patients With Rheumatoid Arthritis Who Completed Trial 0881A1-301-EU in Spain

NCT ID: NCT00195364

Last Updated: 2009-06-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

93 participants

Study Classification

OBSERVATIONAL

Study Start Date

2003-07-31

Study Completion Date

2008-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate long-term safety of etanercept in patients with rheumatoid arthritis who successfully have completed open-label safety study 0881A1-301-EU

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study Evaluating Etanercept in Patients With Rheumatoid Arthritis(RA), Juvenile Idiopathic Arthritis (JIA), or Psoriatic Arthritis (PsA) in Spain

NCT00195377

Arthritis, Psoriatic Arthritis, Rheumatoid
COMPLETED

Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis

NCT00913458

Active Rheumatoid Arthritis Arthritis, Rheumatoid Rheumatoid Arthritis
COMPLETED PHASE4

Study Evaluating the Efficacy and Safety of Etanercept

NCT00546533

Rheumatoid Arthritis
COMPLETED PHASE4

Study Comparing Etanercept in Combination With Methotrexate in Subjects With Rheumatoid Arthritis

NCT00565409

Arthritis, Rheumatoid
COMPLETED PHASE4

Study Evaluating Etanercept in Subjects With Ankylosing Spondylitis in Spain

NCT00873730

Ankylosing Spondylitis
COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatoid Arthritis Inflammation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Etanercept

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* To have completed 0881A1-301-EU study in Spain
* Clinical diagnosis by ACR revised criteria of rheumatoid arthritis.

Exclusion Criteria

* Hypersensibility to etanercept or any of its components
* Significant concurrent medical disease
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Monitor

Role: STUDY_DIRECTOR

Wyeth is now a wholly owned subsidiary of Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Madrid, Madrid, Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0881A1-301, 101492

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real-world Clinical Practice, Using Data Collected by the British Society of Rheumatology Biologics Registry
NCT01646385 COMPLETED
Study Evaluating the Clinical and Therapeutic Management of Rheumatoid Arthritis in Spain
NCT00881881 COMPLETED
Intra-Articular Injection of Etanercept in Patient Suffering From Rheumatoid Arthritis : a Double-Blind Randomized Study
NCT00522184 COMPLETED PHASE3
Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis
NCT00962741 COMPLETED PHASE3
An Open-Label, Multicentre, Long-Term Extension Study of Etanercept in Ankylosing Spondylitis
NCT00421980 COMPLETED PHASE3
Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Rheumatologists
NCT00293722 COMPLETED
Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept
NCT01901185 COMPLETED PHASE3
Open-Label Study Comparing Etanercept to Conventional Disease Modifying Antirheumatic Drug (DMARD) Therapy
NCT00848354 COMPLETED PHASE4
Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis
NCT01421069 COMPLETED PHASE3
Good EULAR Response In Patients With Early Rheumatoid Arthritis
NCT01558089 COMPLETED
Study Evaluating the Safety of Enbrel (Etanercept)
NCT00683384 COMPLETED
Study Evaluating Safety and Adherence to Treatment With Etanercept in Adults With Psoriatic Arthritis
NCT00938015 COMPLETED
Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis
NCT00245960 COMPLETED PHASE4
Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Dermatologists
NCT00293709 COMPLETED
Etanercept SFP in RA Patients
NCT00413452 COMPLETED PHASE3
Study Evaluating the Efficacy of Enbrel (Etanercept) in Subjects in Japan
NCT00503503 COMPLETED
Study of Etanercept in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Adalimumab or Infliximab Plus Methotrexate
NCT01783015 TERMINATED PHASE4
Study Comparing Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept
NCT00459706 COMPLETED PHASE3
Study Evaluating Etanercept for the Treatment of Refractory Heel Enthesitis in Spondylarthropathy
NCT00420303 COMPLETED PHASE4
Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission
NCT02373813 COMPLETED PHASE3
Study to Assess the Immunogenicity, Safety, and Efficacy of High Capacity Process Etanercept in Rheumatoid Arthritis Subjects
NCT02378506 COMPLETED PHASE3
An Observational, Retrospective, Multicenter, National Study for the Monitoring of Subjects Who Participated in the LoadET Clinical Trial
NCT01793285 COMPLETED
Study Comparing Etanercept and Methotrexate vs. Methotrexate Alone in Rheumatoid Arthritis
NCT00195494 COMPLETED PHASE4
Study Comparing Etanercept Plus Methotrexate to Either Etanercept or Methotrexate Alone in Rheumatoid Arthritis.
NCT00393471 COMPLETED PHASE3
A Study to Learn About the Adherence and Clinical Outcomes in Colombian Patients With an E-Device for Etanercept Administration in Rheumatoid Arthritis
NCT05891600 TERMINATED